Finally, ASN007, an ERK1/2 inhibitor, is being tested in patients with BRAF fusion or non-V600 mutations to assess the effects of direct ERK inhibition, a downstream effector in BRAF-mutated cancers [42]. Here, BRAF is linked to cancer.